BlackRock Health Sciences Trust has seen some strong performance recently, yet still trades at a -7.8% discount to NAV, offering compelling value. BME removed its options-writing strategy, eliminating upside caps and shifting focus to long-term capital appreciation in health sciences equities. Despite sector volatility and UNH headwinds, BME remains diversified in healthcare exposure, but some ...
I rate BlackRock Health Sciences Trust a Buy for income-focused investors seeking long-term, buy-and-hold exposure to blue-chip healthcare stocks. BME trades at a -7.8% discount to NAV and offers a monthly distribution yielding approximately 8%, supported by consistent, rising dividends. Recent political pressure on healthcare has depressed valuations, but I expect portfolio holdings like Eli L...
The broader equity indexes continue to look strong, led by mega-cap tech, which has helped push the markets to all-time highs. With hitting new all-time highs, I continue to allow my cash pile to build up instead of putting it all to work at what looks like elevated levels. That said, I make some purchases every month to help grow cash flow over time and to capitalize on pockets of opportunity.
Shares in B&M fell more than 19% on Monday after the UK discount retailer admitted a £7 million accounting error that will hit its earnings and trigger a leadership change. The company said that overseas freight costs were not correctly recognized in its accounts following an operating system update earlier this year.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.